JAMA Network summarizes VESALIUS-CV trial results that intensive LDL-C lowering with evolocumab plus statin reduced first major cardiovascular events in patients with diabetes without known significant atherosclerosis.
Evolocumab for Heart Protection in People With Diabetes
intensive LDL-C lowering with evolocumab plus statin reduced risk of first major cardiovascular event
VESALIUS-CV trial
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare